TrialTrials2015

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.

Denise A Yardley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.